Propecia vs Finpecia: Is the Generic Finasteride Identical to the Brand?

✓ Medically reviewed by  ·  Last reviewed: May 2026

Morgan Ellis

Pharmacy Researcher · 8 years experience

Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.

Finasteride is the most-prescribed hair-loss medication in the world. Merck’s original Propecia approval came in December 1997 for male androgenetic alopecia after the company’s earlier Proscar (finasteride 5 mg for benign prostatic hyperplasia) revealed an unexpected hair-regrowth side effect at higher doses. The Propecia clinical program — Kaufman and colleagues’ 1,553-man, 2-year randomised controlled trial¹ — established that finasteride 1 mg daily produces a meaningful increase in hair count and a reduction in hair-loss progression in roughly 80% of treated men, with maximal effect at approximately 12–24 months of continuous use.

Merck’s US composition patents on finasteride expired in 2014, and FDA-approved generic finasteride entered US retail pharmacies that year. Outside the US, generic finasteride entered numerous export markets earlier. Finpecia, manufactured by Cipla Ltd in Mumbai, is among the most widely distributed WHO-GMP generic finasteride products globally, and has been on the market under the Finpecia brand for over two decades.

This guide compares Propecia and Finpecia on active ingredient, dose, bioequivalence, mechanism, the safety conversation around sexual side effects, and the manufacturing-vs-pricing logic that produces the gap.

TL;DR comparison table

Both tablets contain the same molecule: finasteride 1 mg

Finasteride is a 4-azasteroid synthetic compound that selectively inhibits the type II isoenzyme of 5α-reductase — the enzyme responsible for converting circulating testosterone into dihydrotestosterone (DHT), the more potent androgen implicated in androgenetic alopecia and prostate enlargement. Merck’s Propecia approval was based on the Kaufman et al. (1998) trial¹, which demonstrated that 1 mg daily produced a 17% increase in baseline hair count at 1 year and 12% increase at 2 years versus 7% loss in the placebo group. The 5-year extension data from Kaufman and Olsen² confirmed durable effect with continuous use.

The same molecule at the 5 mg dose has been FDA-approved as Proscar for benign prostatic hyperplasia since 1992. Finasteride at 1 mg suppresses scalp DHT by approximately 60% from baseline. The mechanism is identical between brand and generic.

Bioequivalence

FDA and WHO bioequivalence criteria require identical API at identical dose, with human PK studies confirming Cmax and AUC within 80–125% of reference. Both Propecia and Finpecia contain finasteride 1 mg. Generic finasteride sold in US retail pharmacies since 2014 carries FDA Orange Book AB ratings. Finpecia, because it is not marketed in the United States, does not carry an FDA AB rating, but Cipla’s manufacturing facility is WHO-GMP certified and applies the same Cmax/AUC criterion as FDA. Both produce equivalent plasma finasteride concentrations at equivalent doses.

How finasteride works

Androgenetic alopecia is driven by genetically-determined sensitivity of scalp follicles to dihydrotestosterone. Affected follicles undergo a process called miniaturisation — the anagen (growth) phase shortens, hair shafts become finer and shorter, and after enough cycles the follicle is no longer producing visible terminal hair.

Finasteride inhibits 5α-reductase type II, the dominant isoenzyme in scalp and prostate tissue. Reduced DHT means reduced miniaturisation pressure. In already-miniaturised follicles that have not yet exited the growth cycle entirely, the change can reverse partially, producing the visible regrowth seen in trials. In follicles that have already become dormant (“scarring” androgenetic loss after years of progression), finasteride preserves what remains but does not restore them.

This dynamic produces the most important practical fact about finasteride: earlier intervention preserves more hair. Men starting finasteride at 25 with thinning crown lose far less than men starting at 40 with established Norwood IV pattern. The drug is preservative-first; regrowth is the secondary benefit when miniaturised follicles re-enter the growth cycle.

Side effects: the sexual side-effect conversation

Finasteride’s safety profile is well-documented over 25+ years of post-market use. The most-discussed adverse effects are sexual: decreased libido, erectile dysfunction, and decreased ejaculate volume. The original Kaufman trial reported rates of approximately 1.8% for decreased libido and 1.3% for ED in the finasteride arm versus 1.3% and 0.7% in the placebo arm.¹ In most cases, sexual symptoms resolve with discontinuation; in a small subset of men, symptoms have been reported to persist after stopping, a syndrome called “post-finasteride syndrome” (PFS).

The PFS controversy is genuine. The original trial data does not support a meaningful persistent-symptom signal, but post-market case reports and a small body of patient-advocacy-driven research suggest a subset of men may experience prolonged sexual or affective symptoms. The mechanism, prevalence, and reversibility of PFS are not fully established. Pre-emptive considerations for any user:

• The molecule is the same brand vs generic. PFS, if real, is a property of finasteride, not the manufacturer.
• Discontinue the drug if sexual side effects develop, rather than persisting through them.
• The risk-benefit calculation favours finasteride for the majority of men with androgenetic alopecia — but it is a personal decision, made with full awareness of the discussion.

Other documented adverse effects: breast tenderness or gynaecomastia (~0.5%), depression (signal, magnitude debated), high-grade prostate cancer (REDUCE trial signal at the 5 mg dose; clinical relevance at 1 mg uncertain).

Contraindications

Manufacturer disclosure: who makes Finpecia?

Finpecia is manufactured by Cipla Ltd, headquartered in Mumbai — one of the largest WHO-GMP-certified generic manufacturers globally. Cipla holds approvals from the US FDA, UK MHRA, WHO Prequalification, and a long list of national regulators. Cipla’s finished-product release for Finpecia 1 mg includes HPLC content uniformity assay, dissolution testing per USP, and stability monitoring per ICH guidelines. Certificates of Analysis are available on request through MedsBase customer support — provide your order ID and the batch number from your blister.

How to order Finpecia from MedsBase

Finpecia ships worldwide from MedsBase in discreet packaging (plain envelope, no medication name on the exterior). Payment is accepted via crypto (USDT, BTC, ETH via Plisio), credit card via a regulated crypto on-ramp (statement descriptor is the on-ramp provider name — a regulated card-payment processor — never MedsBase), or SEPA bank transfer where available. See our credit card payment guide. Every order is covered by the MedsBase Reshipment Assurance Policy.

For maximum hair-loss outcomes, finasteride is often combined with topical minoxidil. The MedsBase Hair Loss Stack bundles Finpecia with Tugain (minoxidil) at the standard combination doses. Our companion piece Rogaine vs Tugain covers minoxidil specifically, and the comparison Avodart vs Dutas covers dutasteride — the more-potent 5α-reductase inhibitor used by men who don’t respond adequately to finasteride.

Who should choose which?

• Insured US user starting finasteride: generic FDA-approved finasteride from US retail pharmacies at $10–$25/month is affordable and the supply chain is regulated. Branded Propecia is rarely necessary unless a prescriber objects to generic substitution.
• Long-term user paying out-of-pocket: finasteride is a multi-decade commitment for most men — you stay on it as long as you want the benefit. The cost differential compounds. Finpecia at $8–$15/month vs branded Propecia at $60–$90/month is the difference between a $1,200-per-decade and a $9,000-per-decade habit, for identical pharmacology.
• Non-US user: Finpecia is the practical default. WHO-GMP manufacture, Cipla’s decades-long quality record, and worldwide shipping make it the standard generic finasteride in most markets.
• User who doesn’t respond to 1 mg finasteride after 12 months: the next escalation is usually dutasteride (Avodart or Dutas), which inhibits both type I and type II 5α-reductase isoenzymes and produces ~95% scalp DHT suppression vs ~60% for finasteride.

Pricing context: The brand-vs-generic price comparison on this page is one entry in MedsBase’s broader Brand-vs-Generic Medication Pricing Index — a quarterly-updated reference covering 15 brand-vs-generic pairs across ED, GLP-1, hair-loss, PrEP, and cosmetic clusters, with full methodology and citation disclosure.

Frequently Asked Questions

Is Finpecia literally the same drug as Propecia?

Yes. Both contain finasteride 1 mg as the active ingredient. The mechanism, onset, half-life, response rate, and side-effect profile are pharmacologically identical. The differences are the manufacturer, the inactive excipients, and the price.

Is Finpecia FDA-approved?

No. Finpecia is not registered with the US FDA because it is not marketed in the United States. However, Cipla manufactures Finpecia under WHO-GMP certification, which applies the same bioequivalence and quality-control standards used by the FDA. Generic finasteride products that ARE sold in US pharmacies are FDA Orange Book AB-rated and therapeutically substitutable for Propecia.

How long until I see results?

Reduced shedding is usually noticeable within 3–6 months. Visible regrowth in miniaturised follicles takes 12–24 months. Maximum effect is observed around month 24. This timeline is intrinsic to the hair-growth cycle, not the brand — Finpecia and Propecia produce results on the same schedule.

What happens if I stop taking it?

Within 6–12 months of discontinuation, scalp DHT returns to pre-treatment levels and hair loss resumes from where it was paused. The hair gained or preserved during treatment is lost over the subsequent 12–24 months. Continuous use is required to maintain effect; there is no “cure” window.

Will I lose more hair when I first start (the “shed”)?

Some men experience a 4–8 week shedding episode after starting finasteride or after dose changes. This represents the synchronisation of follicles entering and exiting growth phases as the DHT environment changes, and is generally followed by improved overall density. It is not a sign that the drug is failing.

What’s the deal with post-finasteride syndrome (PFS)?

PFS describes persistent sexual or affective symptoms reported by a subset of men after stopping finasteride. The original trial data does not support a meaningful persistent-symptom signal at expected rates, but post-market case reports and patient-advocacy research describe a subset of cases. The mechanism, prevalence, and reversibility are not fully established. Discontinue the drug if sexual side effects develop, rather than persisting through them. PFS, if real, is a property of the finasteride molecule, not specific to brand or generic.

Is the topical/spray version of finasteride better than oral?

Topical finasteride is being studied as an alternative with potentially fewer systemic side effects. Early trial data suggest similar scalp DHT suppression with reduced serum DHT changes. It is not yet FDA-approved in the US. Compounded topical finasteride is available through some telehealth platforms. Long-term efficacy and safety data are less established than for oral finasteride.

Should I combine Finpecia with minoxidil?

The most-studied combination for male-pattern hair loss is finasteride 1 mg oral + minoxidil 5% topical. Combined response rates exceed either monotherapy in randomised trials. The MedsBase Hair Loss Stack bundles both at standard combination doses. See our Rogaine vs Tugain guide for the minoxidil-specific brand-vs-generic comparison.

Sources

1. Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetic alopecia. Journal of the American Academy of Dermatology. 1998;39(4 Pt 1):578–589.
2. Kaufman KD, Olsen EA, Whiting D, et al. Long-term (5-year) multinational experience with finasteride 1 mg in the treatment of men with androgenetic alopecia. European Journal of Dermatology. 2002;12(1):38–49.
3. US Food and Drug Administration. NDA 020788, Propecia (finasteride 1 mg). Approval letter, 22 December 1997.
4. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer (PCPT). New England Journal of Medicine. 2003;349(3):215–224.
5. Cipla Ltd. WHO-GMP certification under the Indian Central Drugs Standard Control Organisation; multiple national regulatory approvals.

Last clinically reviewed: 18 May 2026.

Written by

Sophie Chen

Pharmaceutical Content Researcher · 8 years experience

Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.